Results 11 to 20 of about 827 (180)

Resistance of Acinetobacter baumannii Complex Clinical Isolates to Sulbactam–Durlobactam: A Systematic Review of Data from In Vitro Studies [PDF]

Pathogens
Introduction: Due to the limited therapeutic options for patients with Acinetobacter baumannii complex infections, a new combination antimicrobial agent, sulbactam–durlobactam, has been developed.
Matthew E. Falagas, Laura T. Romanos, Dimitrios Ragias, Charalampos Filippou   +3 more
doaj   +4 more sources

Sulbactam-durlobactam improves cephalosporin and carbapenem susceptibility and time-kill effect against Mycobacterium abscessus [PDF]

Microbiology Spectrum
Despite the long therapy duration, the treatment outcomes for Mycobacterium abscessus lung disease (MAB-LD) are very poor. β-Lactams are among the recommended drugs for the treatment of MAB-LD; however, they are prone to hydrolysis by MAB β-lactamase ...
Avneesh Shrivastava, Gunavanthi D. Boorgula, Sanjay Singh, Danaleigh Stiles, Pamela J. McShane, Megan Devine, Tawanda Gumbo, Shashikant Srivastava   +7 more
doaj   +4 more sources

Activity of Sulbactam-Durlobactam and Comparators Against a National Collection of Carbapenem-Resistant Acinetobacter baumannii Isolates From Greece [PDF]

Frontiers in Cellular and Infection Microbiology, 2022
BackgroundAcinetobacter baumannii is a leading cause of healthcare-associated infections worldwide, due to both its persistence in the hospital setting and ability to acquire high levels of antibiotic resistance. Carbapenem-resistant A.
Maria Siopi, Spyros Pournaras
exaly   +6 more sources

In vitro activity of sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii and mechanisms of resistance [PDF]

Journal of Global Antimicrobial Resistance, 2022
: Objectives: Multidrug-resistant Acinetobacter baumannii (MDR-Ab), particularly strains producing oxacillinase (OXA)-type carbapenemases, have rapidly emerged in health care settings as a frequent cause of serious infections with limited treatment ...
Jacqueline Findlay, Laurent Poirel, Maxime Bouvier, Patrice Nordmann   +3 more
doaj   +6 more sources

Susceptibility toward cefiderocol and sulbactam-durlobactam in extensively drug-resistant Acinetobacter baumannii detected from ICU admission screening in Hanoi, Vietnam, 2023 [PDF]

Microbiology Spectrum
Infections due to carbapenem-resistant Acinetobacter baumannii (CRAB) pose significant clinical challenges due to limited treatment options. In this study, we investigated the molecular epidemiology, resistance profiles, and genomic characteristics of ...
Sébastien Boutin, Nguyen Quang Toan, Thi Anh Mai Pham, Truong Nhat My, Nguyen Thi Kim Phuong, Bui Tien Sy, Nguyen Van Trong, Lisa Göpel, Leo Huber, Kaan Kocer, Le Thi Kieu Linh, Tran Thanh Tung, Nguyen Trong The, Le Huu Song, Thirumalaisamy P. Velavan, Dennis Nurjadi   +15 more
doaj   +2 more sources

Antimicrobial susceptibility to last-resort antibiotics in carbapenemase-producing bacteria from Ukrainian patients [PDF]

Microbiology Spectrum
Since March 2022, an increase was observed in multidrug-resistant microorganisms (MDRO), associated with the hospital transfer of Ukrainian patients. The goal was to collect phenotypic susceptibility data and assess clinical implications.
Nelianne J. Verkaik, Cornelia C. H. Wielders, Hans den Boer, Diana Langerak, Marius Vogel, Sandra Witteveen, Angela de Haan, Jeroen Bos, Mireille van Westreenen, Daan W. Notermans, Antoni P. A. Hendrickx   +10 more
doaj   +8 more sources

Sulbactam-durlobactam susceptibility test method development and quality control ranges for MIC and disk diffusion tests [PDF]

Journal of Clinical Microbiology
ABSTRACT Sulbactam-durlobactam is a β-lactam/β-lactamase inhibitor combination developed to treat hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus complex (ABC).
Sarah M McLeod, Nicole M Carter, Michael D Huband   +2 more
exaly   +4 more sources

The epidemiological and molecular characteristics and sulbactam-durlobactam susceptibility of carbapenem-resistant Acinetobacter baumannii in a Chinese teaching hospital

Journal of Global Antimicrobial Resistance
: Objectives: This study aimed to investigate sulbactam-durlobactam (SUL-DUR) susceptibility and molecular features of carbapenem-resistant Acinetobacter baumannii (CRAB) isolates from a Shenzhen teaching hospital. Methods: A retrospective study on CRAB
Hanlian Huang, Qiaomin Zhang, Shaobo Li, Xiaoyan Dai, Zhongbiao Chen, Guili Zhang, Wen Ma, Hongwei Shen   +7 more
doaj   +3 more sources

New Perspectives on Antimicrobial Agents: Sulbactam-durlobactam. [PDF]

Antimicrob Agents Chemother
ABSTRACT Infections due to Carbapenem-resistant Acinetobacter baumannii (CRAB) are a significant burden and are associated with devastating outcomes. Subsequently, CRAB is recognized as an urgent threat to human health by the United States (US) Centers for Disease Control ...
Pogue JM, Harrington J, Wangchinda W, Kaye KS.   +3 more
europepmc   +3 more sources

Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates of Acinetobacter baumannii. [PDF]

Antimicrob Agents Chemother, 2023
ABSTRACTAcinetobacter baumannii-calcoaceticuscomplex (ABC) causes severe infections that are difficult to treat due to pre-existing antibiotic resistance. Sulbactam-durlobactam (SUL-DUR) is a targeted β-lactam/β-lactamase inhibitor combination antibiotic designed to treat serious infections caused byAcinetobacter, including multidrug- and carbapenem ...
Moussa SH, Shapiro AB, McLeod SM, Iyer R, Carter NM, Tsai Y-K, Siu LK, Miller AA.   +7 more
europepmc   +3 more sources